Milestone Scientific Reports Financial Results for Third Quarter 2026
Key Highlights
- ➤Medical segment revenue grew 136% year-over-year.
- ➤Q3 revenue $2.2 million, down 5.9% year-over-year.
- ➤Nine-month net loss narrowed to $2.5 million from $4.6 million.
- ➤2026 revenue outlook reaffirmed at $9.8 million-$10.2 million.
- ➤Approximately $400,000 in annual savings targets Q4 profitability.
Expert Statements
Eric Hines, Chief Executive Officer of Milestone Scientific
“During the third quarter, we continued to advance our commercial strategy while maintaining disciplined expense management.”
Eric Hines, Chief Executive Officer of Milestone Scientific
“As anticipated, revenue moderated following the second quarter, which benefited from two large international orders.”
Eric Hines, Chief Executive Officer of Milestone Scientific
“At the same time, we continued to build our commercial pipeline, with completed online demonstrations more than doubling during the first nine months of the year compared with the prior-year period.”
Eric Hines, Chief Executive Officer of Milestone Scientific
“We believe this reflects growing customer engagement and the continued development of a more scalable sales process that can support future growth across our business.”
Eric Hines, Chief Executive Officer of Milestone Scientific
“In dental, we are making progress with four potential distribution channels serving thousands of offices.”
Eric Hines, Chief Executive Officer of Milestone Scientific
“In our medical business, we are gaining traction with major healthcare organizations, highlighted by the initiation of clinical use at Rothman Orthopaedics, a nationally recognized orthopedic organization with 34 locations, and the addition of Pain and Spine Specialists, a 22-location pain management network, to our CompuFlo® Advisor Program.”
Eric Hines, Chief Executive Officer of Milestone Scientific
“These developments represent important milestones in expanding institutional engagement and physician adoption.”
Eric Hines, Chief Executive Officer of Milestone Scientific
“We continue to strengthen reimbursement access, commercial infrastructure and clinical support to accelerate utilization and recurring disposable revenue with more than 500 U.S. commercial leads, our priority is converting that pipeline into active accounts and increasing procedure volumes.”
Eric Hines, Chief Executive Officer of Milestone Scientific
“Internationally, we are seeing growing momentum in medical, and we are pursuing go-to-market and licensing initiatives with a few large medical technology organizations.”
Eric Hines, Chief Executive Officer of Milestone Scientific
“Looking ahead, we expect to approach profitability, or be profitable, in the fourth quarter of 2026.”
Eric Hines, Chief Executive Officer of Milestone Scientific
“For 2027, we expect considerably lower losses than in 2026, and our significantly lower expense base positions us to deliver additional profitable quarters, depending on revenue levels.”
Eric Hines, Chief Executive Officer of Milestone Scientific
“We believe quarterly revenue of approximately $2.6 million to $2.7 million would bring us near our profitability threshold, beyond which incremental sales can drive meaningful improvements in operating performance.”
Eric Hines, Chief Executive Officer of Milestone Scientific
“Combined with continued growth in our core dental business and CompuFlo® commercialization, we believe this operating leverage provides a foundation for sustainable growth and long-term shareholder value.”
Expands CompuFlo® Physician Partnerships and Advances Medical Commercialization
Online Demonstrations More Than Double Reflecting Increased Customer Engagement
Get started
Create a free account to read the full story.